RxDoctor Payments Data

James Rogan, MD

Family Medicine · Atlanta, GANPI 1982704300

Payments from drug & device makers

$18,111in general payments, 2019–2025

Across 44 payments — averaging $411.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$10K
  • Romark Laboratories, LC$8K
  • Neurocrine Biosciences, Inc.$257
  • Acadia Pharmaceuticals Inc$253
  • Otsuka America Pharmaceutical, Inc.$157
  • Inspire Medical Systems, Inc.$55
  • plus $182 from 7 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,111 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$371,476
Medicare patients
1,011
Services billed
3,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,172$325,251
Invega SustennaPaliperidone Palmitate39$99,117
BiktarvyBictegrav/Emtricit/Tenofov Ala16$68,080
XareltoRivaroxaban287$63,955
Risperdal ConstaRisperidone Microspheres52$46,542
JanuviaSitagliptin Phosphate183$46,430
RexultiBrexpiprazole35$44,771
JardianceEmpagliflozin110$43,296
OzempicSemaglutide41$42,813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$41,743
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog257$33,695
MyrbetriqMirabegron228$33,611
LinzessLinaclotide53$31,896
TivicayDolutegravir Sodium12$27,977
Atorvastatin Calcium3,952$27,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$325,2511,172 claims
GSKTrelegy Ellipta, Shingrix, Incruse Ellipta, Arexvy, Breo Ellipta$18$105,175279 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Breztri Aerosphere$9,707$63,657269 claims
Otsuka America Pharmaceutical, Inc.Rexulti$157$44,77135 claims
Novo NordiskOzempic$21$42,81341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →